VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer

ABSTRACT: In this study, we compared first-line VIC regimen with chemotherapy plus bevacizumab in Chinese patients with initially unresectable BRAF V600E-mutated mCRC. The principal goal was to evaluate the safety of VIC regimen, and to investigate the tumor response, the radical resectability, and the patient survival.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2748402 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR